Zobrazeno 1 - 5
of 5
pro vyhledávání: '"Quizartinib Dihydrochloride"'
Autor:
Malaz Abutarif, David Jaworowicz, Alexander E. Perl, Jill Fiedler-Kelly, Youngsook Choi, Nigel H. Russell, Siddhartha Ganguly, Alwin Krämer, Ophelia Yin, Mark J. Levis, Samer K. Khaled, Dongwoo Kang, Giovanni Martinelli, Jorge E. Cortes, Elizabeth Ludwig, Hannah Huang
Publikováno v:
Cancer Chemotherapy and Pharmacology
Purpose This analysis evaluated the relationship between concentrations of quizartinib and its active metabolite AC886 and QT interval corrected using Fridericia’s formula (QTcF) in patients with relapsed/refractory acute myeloid leukemia (AML) tre
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::8f76e3afa26bf8e134e7d791e5ced06e
https://doi.org/10.1007/s00280-020-04204-y
https://doi.org/10.1007/s00280-020-04204-y
Autor:
Guy Gammon, Jean Pierre Marie, Denise Trone, Stuart L. Goldberg, Martin S. Tallman, Giovanni Martinelli, Gary J. Schiller, Mark J. Levis, Alexander E. Perl, Hagop M. Kantarjian, Jorge E. Cortes
Publikováno v:
Blood, vol 132, iss 6
Cortes, JE; Tallman, MS; Schiller, GJ; Trone, D; Gammon, G; Goldberg, SL; et al.(2018). Phase 2b study of 2 dosing regimens of quizartinib monotherapy in FLT3-ITD-mutated, relapsed or refractory AML. BLOOD, 132(6), 598-607. doi: 10.1182/blood-2018-01-821629. UCLA: Retrieved from: http://www.escholarship.org/uc/item/1zw0t5wd
Cortes, JE; Tallman, MS; Schiller, GJ; Trone, D; Gammon, G; Goldberg, SL; et al.(2018). Phase 2b study of 2 dosing regimens of quizartinib monotherapy in FLT3-ITD-mutated, relapsed or refractory AML. BLOOD, 132(6), 598-607. doi: 10.1182/blood-2018-01-821629. UCLA: Retrieved from: http://www.escholarship.org/uc/item/1zw0t5wd
This randomized, open-label, phase 2b study (NCT01565668) evaluated the efficacy and safety of 2 dosing regimens of quizartinib monotherapy in patients with relapsed/refractory (R/R) FLT3-internal tandem duplication (ITD)-mutated acute myeloid leukem
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::d9b1c036c9b2563ed059f05d29bb6bcd
https://doi.org/10.1182/blood-2018-01-821629
https://doi.org/10.1182/blood-2018-01-821629
Autor:
Denise Trone, Keith W. Pratz, Jessica K. Altman, Jorge E. Cortes, Martin S. Tallman, James M. Foran
Publikováno v:
American Journal of Hematology
Novel therapies have potential to improve outcomes in patients with acute myeloid leukemia (AML) harboring FLT3-ITD mutations that have high risk of relapse and poor survival following standard of care (SOC) cytarabine/anthracycline-based induction/c
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::e7d883d1daa47525288abed44a56c130
https://doi.org/10.1002/ajh.24974
https://doi.org/10.1002/ajh.24974
Autor:
Jianke Li, Kyriakos P. Papadopoulos, George D. Demetri, Denise Trone, Amita Patnaik, Eytan Ben-Ami
Publikováno v:
BMC Cancer
BMC Cancer, Vol 18, Iss 1, Pp 1-7 (2018)
BMC Cancer, Vol 18, Iss 1, Pp 1-7 (2018)
Background Quizartinib, an inhibitor of class III receptor tyrosine kinases (RTKs), is currently in phase 3 development for the treatment of acute myeloid leukemia (AML) bearing internal tandem duplications in the FLT3 gene. Aberrant RTK signaling is
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::aa695875919bc004a97d2f876e61e5ca
https://pubmed.ncbi.nlm.nih.gov/30081867
https://pubmed.ncbi.nlm.nih.gov/30081867
Publikováno v:
American Journal of Hematology
FLT3-ITD–mutated acute myeloid leukemia (AML) has very high risk of relapse and is associated with poor outcome following allogeneic hematopoietic-cell transplant (allo-HCT). This two-part, phase 1, multicenter, open-label, sequential-group, dose-e
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::723c7a61a1631a2d80b5d99e3e6abd6e
https://pubmed.ncbi.nlm.nih.gov/29090473
https://pubmed.ncbi.nlm.nih.gov/29090473